Biologics Price Competition and Innovation Act: Striking a Delicate Balance Between Innovation and Accessibility

Ude Lu

Follow this and additional works at: https://scholarship.law.umn.edu/mjlst

Recommended Citation
Ude Lu, Biologics Price Competition and Innovation Act: Striking a Delicate Balance Between Innovation and Accessibility, 15 MINN. J.L. SCI. & TECH. 613 (2014). Available at: https://scholarship.law.umn.edu/mjlst/vol15/iss1/26
Biologics Price Competition and Innovation Act: Striking a Delicate Balance Between Innovation and Accessibility

Ude Lu*

The Biologics Price Competition and Innovation Act of 2009 (BPCIA, also known as the Biosimilar Act) was signed into law in 2010 by President Barack Obama as part of the healthcare reform bill. The central mission of the BPCIA is two-fold: (1) providing sufficient incentives for continuous innovations in biologic therapies (i.e., promoting innovation); and (2) lowering the price of biologic therapies (i.e., promoting accessibility). To promote innovation, the BPCIA provides twelve-year Food and Drug Administration (FDA) exclusivity to innovator biologics. This twelve-year FDA exclusivity prevents generic biologics, also known as follow-on biologics (FOBs),

© 2014 Ude Lu

* JD Candidate, University of Minnesota Law School, 2014; PhD, Biomedical Engineering, University of Southern California, 2011. I am deeply indebted to Professor Thomas F. Cotter for providing me with invaluable advice throughout the writing process. I sincerely thank Brian R. Dorn, PhD, JD, for giving me inspiring opinions on the subject matter. I am grateful to my MJLST colleagues Caroline Marsili, Brandon Palmen, Elliot Ferrell, Chris Evans, and Nihal Parkar for their excellent comments and generous assistance. I also thank my lovely wife for her patience and support. The opinions expressed in this article represent my own and not those of my current or future employers.


2. Biologics Price Competition and Innovation Act § 7001(b), 124 Stat. at 804 ("It is the sense of the Senate that a biosimilars pathway balancing innovations and consumer interests [i.e., accessibility] should be established.").

3. Id. § 7002(k)(2)(A), 124 Stat. at 805.
from being approved. To promote accessibility, the BPCIA provides an abbreviated pathway for FOBs—the abbreviated biologic license application (ABLA). The ABLA allows FOB manufacturers to cut short the time and the expensive cost of clinical testing by referring to innovator biologics’ clinical data to establish safety and efficacy.

The goal of this Note is to discuss the advantages and drawbacks of the mechanisms established in the BPCIA and to suggest modifications to strike a better balance between innovation and accessibility. Part I of this Note introduces the legal and scientific background of the BPCIA and Hatch-Waxman Act in order to engage in further analyses. Part II of this Note analyzes the competing interests of innovation and accessibility and suggests a novel six-year data exclusivity and a six-to-twelve-year market exclusivity regulatory scheme. This Note concludes that the current design of the BPCIA tips too favorably toward innovation and compromises accessibility. The suggested six-year data exclusivity and six-to-twelve-year market exclusivity regulatory scheme potentially strike a better balance between innovation and accessibility.

I. BACKGROUND: INTRODUCING THE LEGAL AND SCIENTIFIC BACKGROUND OF THE BPCIA AND THE HATCH-WAXMAN ACT

The BPCIA is highly analogous to the Drug Price Competition and Patent Term Restoration Act introduced in 1984, also known as the Hatch-Waxman Act, which established

4. Id. (stating that the Commissioner of the FDA may not make effective an approval of a generic biologic until a twelve-year period after the referenced biologic was approved). Follow-on biologic (FOB) essentially means the generic version of a biologic pharmaceutical. Agencies, such as the Federal Trade Commission (FTC), and commentators have adopted the term “follow-on biologic” to distinguish it from “generic drug” (i.e., a small-molecule drug that is bioequivalent to a reference small-molecule drug). This is because it is agreed among scientific communities that it is impossible to make a “generic biologic” that is bioequivalent to a reference biologic, as one can with small-molecule drugs. Thus, the term FOB is adopted to emphasize biosimilar and distinguish from bioequivalent.

5. Id. § 7002, 124 Stat. at 805. Section 7002 was subsequently codified in 42 U.S.C. § 262(k) (defining Licensure of Biological Products (LBP)). LBP is an abbreviated pathway to get FDA approval on generic versions of biologic pharmaceuticals. Commentators usually refer to a LBP as an abbreviated biologic license application (ABLA) in recognition of the highly similar structure with abbreviated new drug applications (ANDA) established in the Hatch-Waxman Act.

the abbreviated approval process for small molecule drugs.\textsuperscript{7} Similar to the goals of the BPCIA, the Hatch-Waxman Act tries to balance two competing interests: innovation and accessibility.\textsuperscript{8} To incentivize innovation, the Hatch-Waxman Act provides patent term extension (PTE) that prolongs the patent exclusivity period so that innovator companies have an extended period of market monopoly.\textsuperscript{9} On the other side of the scale, to increase public access to drugs, the Hatch-Waxman Act established an abbreviated new drug application (ANDA) to introduce competing generic drugs through a fast approval process.\textsuperscript{10} The Hatch-Waxman Act establishes the modern generic drug industry and was incredibly successful in increasing the accessibility of small molecule drugs.\textsuperscript{11} In 1984, when the Hatch-Waxman Act was introduced, generic drug use

\textsuperscript{7} Drug Price Competition and Patent Term Restoration (Hatch-Waxman) Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585 (codified as amended in scattered sections of 15, 21, 28, and 35 U.S.C.). The provisions of abbreviated new drug applications (ANDAs) were subsequently codified in 21 U.S.C. § 355(j). ANDAs are similar to 42 U.S.C. § 262(k) ABLAs. Both ANDAs and ABLAs allow generic drug companies to reference the clinical data originally submitted by the innovator drug companies to establish the safety and efficacy of the generic drugs/biologics. This saves generic drug companies a tremendous amount of time and money by avoiding full-scale clinical trials so that generic drugs/FOBs can enter the market quickly after the patent terms of the innovator drugs expire. One major difference between ANDAs and ABLAs is that ANDAs regulate small-molecule drugs and ABLAs regulate biologics.

\textsuperscript{8} Hatch-Waxman Act, 98 Stat. at 1585 (“To amend the Federal Food, Drug, and Cosmetic Act to revise the procedures for new drug applications, to amend title 35, United States Code, to authorize the extensions of the patents for certain regulated products, and for other purposes.”) (emphasis added)). The “revised procedure” for new drug applications refers to ANDAs. ANDAs increase drug accessibility by introducing generic drug competition quickly after the patents covering the reference drug expire. The “extension of patent” term refers to patent term extension (PTE), which extends the patent term by 50% of the FDA approval time. PTE is to incentivize innovation. See Colleen Kelly, The Balance Between Innovation and Competition: The Hatch-Waxman Act, the 2003 Amendments, and Beyond, 66 FOOD & DRUG L.J. 417, 418 (2011).

\textsuperscript{9} See Hatch-Waxman Act § 201.

\textsuperscript{10} See Hatch-Waxman Act § 101.

\textsuperscript{11} Examining the Senate and House Versions of the “Greater Access to Affordable Pharmaceuticals Act”: Hearing Before the S. Comm. on the Judiciary, 108th Cong. 7–13 (2003) (statement of Daniel E. Troy, Chief Counsel, U.S. Food & Drug Administration). The FDA stated that the Hatch-Waxman Act was working well. Since the Hatch-Waxman Act’s passage in 1984, 10,000 generic drugs have entered the market. By 2003, 50% of the prescriptions were filled by generic drugs. \textit{Id.}
was less than 20% of all prescription drug use. By 2010, the percentage increased to 78%. The popularity of generic drugs drove down small molecule drug prices by an average of almost 75%. However, the Hatch-Waxman Act regulates only small molecule drugs, not biologics. This is probably because, as of 1984, biologic pharmaceuticals were still in their infancy. In other words, there was no abbreviated approval process for biologics before the BPCIA was signed into law in 2010.

A. SMALL MOLECULE DRUGS v. BIOLOGICS

Biologics are very different from small molecule drugs. Small molecule drugs are chemically synthesized. Biologics

15. Corporate Chronology, GENENTECH, http://www.gene.com/media/company-information/chronology (last visited Nov. 12, 2013). In modern biotechnology, recombinant DNA is the major technology used to create biologics. The first recombinant DNA biologic, human insulin made by Genentech, was approved by the FDA in 1982, only two years before the Hatch-Waxman Act was enacted in 1984. Thus, at the time the Hatch-Waxman Act was enacted, there was no need for an abbreviated pathway for FOBs, because at that time the innovator biologics are all protected by patents. See Trader Thoughts, Biogenerics: Not Yet a Reality in the U.S., SEEKING ALPHA (Dec. 24, 2007), http://seekingalpha.com/article/58230-biogenerics-not-yet-a-reality-in-the-u-s.
18. 42 U.S.C. § 262(i) (2006 & Supp. V 2011) (“[T]he term ‘biological product’ means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, [protein (except any chemically synthesized polypeptide),] or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.”); see also SCHACT & THOMAS, supra note 17, at 5 (stating that chemical drugs are based on small molecules that typically contain dozens of atoms, while biologics are based on macro-molecules that may consist of millions of atoms).
are the products of living cells. Biologics include: “therapeutic serums, toxins, antitoxins, vaccines, blood, blood components or derivatives, allergenic products, proteins, and viruses.”

Compared to small molecule drugs, biologics have much larger molecular weights and much more complicated three dimensional structures. Biologics are usually proteins and antibodies which possess high binding affinity with specific substrates. Unlike small molecule drugs, which usually have larger tolerance to heat or contamination in the production process, biologics are extremely heat-sensitive and susceptible to microbial contamination. A minor change in the manufacturing process, such as a minor change in temperature of cell culture, can change the overall characteristic of a final biologic product. Thus, quality control for biologics is much more costly and complex than for small molecule drugs.

Traditionally, biologics were extracted from animals or humans bodies. This production method is limited in quantity, and obviously undesirable. In 1973, the development of recombinant DNA technology made mass production of biologics possible. Since then, the medical

---

19. SCHACHT & THOMAS, supra note 17, at 5.
22. Simon D. Roger, Biosimilars: How Similar or Dissimilar Are They?, 11 Nephrology 341, 343 (2006) (stating that in assessing efficacy of biosimilars, receptor-binding affinity is an important index).
23. What Are “Biologics” Questions and Answers, FOOD & DRUG ADMIN., http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm133077.htm (last visited Sept. 14, 2013) (“In contrast to most drugs that are chemically synthesized and their structure is known, most biologics are complex mixtures that are not easily identified or characterized. Biological products, including those manufactured by biotechnology, tend to be heat sensitive and susceptible to microbial contamination. Therefore, it is necessary to use aseptic principles from initial manufacturing steps, which is also in contrast to most conventional drugs.”).
25. Id.
27. Id.
importance of biologics has grown exponentially. The FDA states: “biological products often represent the cutting-edge of biomedical research and, in time, may offer the most effective means to treat a variety of medical illnesses and conditions that presently have no other treatments available.”

Conditions currently treated by biologics include diseases such as cancer, arthritis, chronic plaque psoriasis, anemia, and chronic renal failure. Commentators called biologics “the wonder drug” of the 21st Century. In 2007 there were 400 biologics treating more than 200 conditions. By 2011, there were more than 900 biologics in various clinical trial phases targeting more than 100 diseases. There is little doubt that biologics will make up the majority of pharmaceutical therapies to treat the most difficult diseases in the future.

The economic importance of biologics also grew exponentially in the pharmaceutical industry. In 2000, biologics sales accounted for 11% of all drug sales in the United States. By 2005, that figure rose to 18%, and by 2010, it grew to 26% of total consumer spending on pharmaceuticals.
B. THE URGE FOR BIOSIMILARS BEFORE 2010

During 2003 and 2004, patents protecting several multi-billion dollar sale biologics expired.\footnote{Trader Thoughts, supra note 15 (“Patent for Biogen’s Avonex (2006 sales: $1Bn) expired in 2003, Eli Lilly’s Humatrope ($390M) expired in 2003, Genentech’s Humulin ($1Bn) expired in 2004, while the blockbuster anemia drug—Amgen’s Epogen ($2.5 Bn) is set to expire in 2012.”).} Yet innovator companies faced no market competition because, at that time, there was no abbreviated pathway to approve FOBs.\footnote{See SCHACHT & THOMAS, supra note 17, at 5 (stating that prior to the enactment of the BPCIA in 2010, there was no generally applicable abbreviated statutory pathway for FOBs); see also What We Do, DRAGONFLY SCIENCES, http://www.dragonflysciences.com/whatWeDo/index.html (last visited Mar. 30, 2013) (stating that monoclonal antibody (mAB) manufacturers (mAB is a kind of biologic) have enjoyed market monopoly due to both patent protection and the lack of regulatory mechanisms to approve generic versions of biologics).} Since then, there has been increasing pressure on Congress to provide for an abbreviated approval pathway (i.e., biosimilar pathway, similar to ANDA in the Hatch-Waxman Act to approve FOBs).\footnote{ROBERT J. SHAPIRO ET AL., THE POTENTIAL AMERICAN MARKET FOR GENERIC BIOLOGICAL TREATMENTS AND ASSOCIATED COST SAVINGS 1, 2 (2008) available at http://www.sonecon.com/docs/studies/0208_GenericBiologiesStudy.pdf. (“Congress created an accelerated regulatory process for FDA approval of generic pharmaceuticals in 1984, under the Hatch-Waxman Act, but the law covers only traditional, small-molecule pharmaceuticals and not biologics.”); see also Gregory N. Mandel, The Generic Biologies Debate: Industry’s Unintended Admission that Biotech Patents Fail Enablement, 11 VA. J.L. & TECH., Fall 2006, at 1 (“[Generic] manufacturers currently are significantly limited in their ability to sell generic copies of biologics even after the pioneer biologic patents expire. As early biologics are starting to go off-patent, this regulatory mix-up is having a notable impact on the availability of biologics and raising the cost of health care.”).} The pressure on Congress intensified after both the European Union (EU) and Canada implemented their versions of biosimilar pathways in 2004 and 2006 respectively.\footnote{Noel Courage & Ainslie Parsons, The Comparability Conundrum: Biosimilars in the United States, Europe and Canada, 66 FOOD & DRUG L.J. 203, 209–12 (2011).} In 2004, Dr. Carole Ben-Maimon, President of Barr Research, Inc., testified in front of the Senate Judiciary Committee: “[G]eneric competition for biotech pharmaceuticals has the potential to offer consumers dramatic and substantial savings, while also lowering America’s healthcare bill.”\footnote{Law of Biologic Medicine: Hearing Before the S. Comm. of the Judiciary, 108th Cong. 24–25 (2004) (statement of Carole Ben-Maimon, M.D., President and Chief Operating Officer, Barr Research, Inc., Bala Cynwyd, Pennsylvania).} Kathleen Jaeger, the...
president of the Generic Pharmaceutical Association stated in 2005: “Sound science already has enabled citizens in the European Union, Australia, India and South America to have access to these medicines. And, the EU estimates that it will save $2.8 billion from the market entry of just a few products. . . . Clearly, the U.S. must stop dragging its feet.”

In 2009, President Obama also urged Congress to act on a biosimilar pathway: “[W]e need to introduce generic biologic drugs into the marketplace. . . . But right now, there is no pathway at the FDA for approving generic versions of these drugs.”

C. DATA EXCLUSIVITY V. MARKET EXCLUSIVITY

The BPCIA’s mission is to promote both innovation and accessibility of biologics. In striking the balance, the key point is how long of a period of exclusivity the FDA should provide for innovator biologics. Currently, the BPCIA provides a twelve-year FDA exclusivity for a new biologic entity (NBE). A further question is whether this twelve-year exclusivity is data exclusivity or market exclusivity. The statute is currently unclear on this.


46. Lewis Krauskopf, Teva Executive Upbeat on Biogenerics in 2009, REUTERS (Dec. 23, 2008), http://uk.reuters.com/article/2008/12/23/businesspro-us-teva-idUKTRE4BM4OA20081223 (noting the key point in the legislation of the FOB pathway is the amount of exclusivity that would be afforded to brand-name biotech drugs; generic drug makers like Teva want to limit it to seven years, while the brand name companies want fourteen years). Teva is the biggest generic drug company in the world, headquartered in Israel, having 46,000 employees, running annual revenue more than $20 billion in 2012. About Us, TEVAPHARM.COM, http://www.tevapharm.com/About/Pages/AboutUs.aspx (last visited Oct. 10, 2013).


The contrast between data and market exclusivity has significant implications for the general public.\(^\text{49}\) Data exclusivity prohibits FOB manufacturers from relying on the clinical trial data submitted by the innovator companies.\(^\text{50}\) Notice that, by definition, ABLA is a regulatory pathway allowing FOB manufacturers to rely on innovators’ clinical data to establish safety and efficacy.\(^\text{51}\) Thus, if the twelve-year exclusivity is a data exclusivity, it essentially means ABLA is not available to FOB manufactures during the first twelve years after a reference biologic is approved.\(^\text{52}\) Market exclusivity, as opposed to data exclusivity, does not prohibit the FDA from accepting and reviewing an ABLA.\(^\text{53}\) Market exclusivity merely prohibits the FDA from approving an FOB to sell on the market.\(^\text{54}\) In other words, the FDA can accept and review an ABLA but will not approve it until the applicable market exclusivity expires.\(^\text{55}\)

Years of delay in introducing drug price competition equal to the FDA review period of FOBs is the difference between a data or market exclusivity.\(^\text{56}\) This delay of drug price

\(^{49}\) See Kurt R. Karst, Tussle Over BPCIA “Market” Versus “Data” Exclusivity Continues; This Time the Generic Supporters Chime in, FDA L. BLOG (Jan. 21, 2011, 6:38 AM), http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2011/01/tussle-over-bpcia-market-versus-data-exclusivity-continues-this-time-the-generics-side-chimes-in.html (asserting that generic supporters argue that interpreting the twelve-year FDA exclusivity as a data exclusivity, which prevents biosimilar (i.e., ABLA) submission has serious consequences and that consumers will have to endure an unknown period of delay of FDA review and approval that could stretch far beyond the twelve-year total that was set in the legislation).

\(^{50}\) See Bagley, supra note 48, at 14 (noting that the five-year data exclusivity period for a new chemical entity (NCE) prevents generic drug companies from even filing an ANDA).

\(^{51}\) 42 U.S.C. § 262(k)(2)(A) (stating that the biological product can establish biosimilarity to a reference product based upon data derived from analytical studies, animal studies, and clinical studies).

\(^{52}\) See Bagley, supra note 48, at 22.

\(^{53}\) See id. at 15–18 (explaining market exclusivity within the context of pediatric testing exclusivity and orphan drug exclusivity). Market exclusivity does not prevent generic companies from filing an ANDA, as in data exclusivity. During the market exclusivity period, the FDA can receive and review an ANDA but will not approve it until the reference drug’s market exclusivity expires.

\(^{54}\) Id.

\(^{55}\) Id.

\(^{56}\) See Karst, supra note 49 (stating that data exclusivity which prevents ABLA submission stretches the market monopoly far beyond the twelve-year period); see also infra note 242 (establishing that a reasonable expectation for the FDA to approve an ABLA is about three to four years).
competition in biologics translates to tens of billions of medical expenses to the general public.\textsuperscript{57}

D. BIOSIMILAR V. INTERCHANGEABLE

The BPCIA provides two categories of FOBs: (1) biosimilar, defined in 42 U.S.C. § 262 (k)(2); and (2) interchangeable, defined in 42 U.S.C. § 262 (k)(4).\textsuperscript{58} An FOB is biosimilar to a referenced biologic if the FOB (1) shows sufficient similarity through analytical, animal, and clinical studies; (2) utilizes the same therapeutic mechanism; (3) is used for the same indications; (4) uses the same drug administration and dosages; and (5) the quality control of the manufacture facility of the FOB assures safety, purity, and potency.\textsuperscript{59} An FOB is interchangeable with a referenced biologic, if it is (1) biosimilar; (2) expected to produce the same clinical result as reference drug in any given patient; and (3) the risk of switching between the FOB and reference drugs is not greater than the risk of continuous use of the reference drug.\textsuperscript{60} If an FOB is biosimilar, it has to be prescribed by the medical doctor; on the other hand, if an FOB is interchangeable, it can be switched by a pharmacist without informing the patient or the prescribing doctor.\textsuperscript{61}

\textsuperscript{57} Saurabh Aggarwal, What’s Fueling the Biotech Engine—2011 to 2012, 30 NATURE BIOTECHNOLOGY 1191, 1192 (2012) (showing that the annual sales of biologics was (in billions USD) $44.5 in 2007, $46.5 in 2008, $48.2 in 2009, $51.3 in 2010, and $53.8 in 2011). From the experience of small-molecule drugs, the price of a brand-name drug drops 50\% instantly in the first year of the introduction of generic drug competition. Applying this dropping rate to biologics means the general public can save around $20 billion to $25 billion each year through drug-price competition, assuming each innovator biologic has an FOB competitor.


\textsuperscript{59} § 262(k)(2).

\textsuperscript{60} § 262(k)(4).

\textsuperscript{61} § 262(i)(3) (“The term ‘interchangeable’ or ‘interchangeability’, in reference to a biological product that is shown to meet the standards described in subsection (k)(4), means that the biological product may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product.”).
II. ANALYSIS: PROMOTING INNOVATION AND ACCESSIBILITY

A. PROMOTING INNOVATION

The general public benefits from the innovation of new biologics because they provide life-quality improving treatments that did not exist before. It is important for the government to offer proper incentives to insure innovator drug companies in recouping the heavy investments and ensure their ability to fund new research to continue innovation. Commentators view the twelve-year FDA exclusivity provided in 42 U.S.C. § 262(k)(7)(A) to be the most important and effective measure in the BPCIA to promote innovation.

This twelve-year FDA exclusivity is complementary to, independent from, and even stronger than patent exclusivity. There are four reasons to support these assertions. First, this NBE exclusivity de facto covers more than one patent. The FDA grants this exclusivity on each new biological entity, which covers 2.7 patents on average. Second, this twelve-year exclusivity is likely to last longer than the active patent life.

62. See Patton, supra note 32 (stating that biologics are the wonder drugs of this age, promising to treat AIDS, cancer, Alzheimer’s, and multiple sclerosis).

63. Henry Grabowski, Follow-On Biologics: Data Exclusivity and the Balance Between Innovation and Competition, 7 NATURE REVIEWS DRUG DISCOVERY 479, 486 (2008) (stating that developing a new biologic entity costs around $1.24–$1.33 billion, and the cost has to be recouped from the sales of approved product).

64. Don Ware & Nick Littlefield, FOLLOW-ON BIOLOGICS AND PATENT REFORM: WILL THEY DISCOURAGE VENTURE CAPITAL INVESTMENT IN THE BIOTECHNOLOGY INDUSTRY? 5 (2009), available at http://www.foleyhoag.com/publications/ebooks-and-white-papers/2008/june/follow-on-biologics-and-patent-reform (“One of the issues of greatest importance involves the number of years of data exclusivity provided for a licensed biological product. ‘Data exclusivity’ refers to a period of time during which an FOB applicant is precluded from relying on clinical data from the innovator product as evidence of safety and effectiveness. Too short an exclusivity period could serve as a serious deterrent for VC investors if they believe the risk of early market entry of a biosimilar product will reduce the profitability of the branded compound. The loss of VC funding would seriously hinder, if not destroy, biotechnology innovation.”).

65. Grabowski, supra note 63, at 480 (stating that data exclusivity provides an important back-up to the patent system).


67. Id.
during which innovator companies recoup their investments.\textsuperscript{68} Third, FDA exclusivity is independent from patent exclusivity.\textsuperscript{69} Even if the patents covering the biologic are invalidated, the FDA exclusivity still stands.\textsuperscript{70} Fourth, FDA exclusivity practically eliminates the design-around issues.\textsuperscript{71} Innovator companies often rely on method patents to protect the manufacturing process of the final products.\textsuperscript{72} These method patents are relatively easy to design around.\textsuperscript{73} FDA exclusivity prevents design-around because FDA exclusivity protects the final product, regardless of how it is manufactured.\textsuperscript{74} Even if a generic company develops a different manufacturing process to make the same biologic that does not infringe the innovator companies’ patents, the final product is still precluded from FDA approval.\textsuperscript{75}

The importance of using FDA exclusivity in promoting innovation can be further analyzed in three different perspectives: cost of capital and time in research and development, patent uncertainty, and drops in new drug applications.

\textsuperscript{68} Linfong Tzeng, \textit{Follow-on Biologics, Data Exclusivity, and the FDA}, 25 BERKELEY TECH. L.J. 135, 156 (2010) (stating that the twelve-year exclusivity runs potentially longer than patent protection). A detailed calculation is provided later in this Note showing that this twelve-year exclusivity lasts longer than an average, remaining active patent term of a biologic.

\textsuperscript{69} Id. (explaining that FDA exclusivity is independent from patent exclusivity and stating that “[t]his is potentially troubling as data exclusivity is unchallengeable in court” (emphasis added)). Whether the FDA decision in granting data exclusivity is challengeable is a complex legal issue in administrative law, which is out of the scope of this Note. My research shows that there is indeed no judicial challenge to an FDA decision granting data exclusivity.

\textsuperscript{70} Id.

\textsuperscript{71} See id. at 154–55.

\textsuperscript{72} See Hemphill & Sampat, \textit{supra} note 66, at 330.

\textsuperscript{73} BIOTECH. INDUSTRY ORG., FTC BIOSIMILARS REPORT REBUTTAL (2009), available at http://www.bio.org/sites/default/files/FTC_biosimilars_report_rebuttal.pdf (stating that patents covering biologics are often narrower and easier to “design around” than those of small-molecule drugs, and innovator companies need additional data exclusivity to secure their market monopolies).

\textsuperscript{74} See Tzeng, \textit{supra} note 68, at 154–55.

\textsuperscript{75} Id.
1. Cost of Capital and Time in Research and Development

The cost to bring a biologic drug to the market is higher than that for a small-molecule drug.\footnote{Joseph A. DiMasi & Henry G. Grabowski, The Cost of Biopharmaceutical R&D: Is Biotech Different?, 28 MGMT. & DECISION ECON. 469, 477 (2007) (showing that, on average, it costs $1.24 billion to bring a biologic to the market compared to $899 million for a small-molecule drug).} This higher cost is partly due to the high manufacture quality required in making a biologic.\footnote{FDA, SCIENTIFIC CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY TO A REFERENCE PRODUCT 5–6 (2012) [hereinafter SCIENTIFIC CONSIDERATIONS], available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf (stating that different cell lines, raw materials, equipment, processes, process controls, and acceptance criteria are all likely to affect the quality of produced biologics).}

Any minor change in the manufacture or drug-delivery process can change the overall characteristic of a final biologic product.\footnote{See Nowicki, supra note 24, at 268.} For example, with exactly the same manufacturing process, a manufacturer of interferon beta-1a produced two batches of products with drastically different immunogenicity.\footnote{Sungae S. Park et al., Biochemical Assessment of Erythropoietin Products From Asia Versus US Epoetin Alfa Manufactured by Amgen, 98 J. PHARMACEUTICAL SCI. 1688, 1689 (2009). Biologics are proteins. The folding process of a protein is highly sensitive to environmental conditions (e.g., temperature, ion concentration, virus/bacteria contamination, etc.). A protein that is properly folded (i.e., having a proper three-dimensional structure) can be an effective drug. In contrast, the same protein that is not properly folded can cause serious immune response and death.} One batch was safe and effective, yet another batch caused serious immune responses.\footnote{Id.} The only difference between the two batches was the manufacture site.\footnote{Id.} The manufacturing conditions that affect the properties of biologics generally include: the cell lines used to produce the biologics, culture/fermentation conditions, purification procedures, and container closure/packaging systems.\footnote{Id.} Thus, a much higher quality control standard is required for biologics than for small molecule drugs.\footnote{SCIENTIFIC CONSIDERATIONS, supra note 77, at 4 (stating that even minor structural differences, including certain changes in glycosylation patterns, can significantly affect a protein’s safety, purity, and potency). It will be important to evaluate these differences.} This high quality standard translates to higher capital investment in research and
development. In addition, the sensitive nature of biologics results in a longer period of clinical trial and regulatory review. The average period of clinical trial and regulatory review for a biologic is 97.7 months, which is 7 months longer than for a small-molecule drug.

Higher manufacturing cost translates to higher drug price, which consequently reduces the market demand. This reduction of market demand negatively impacts the profitability of innovator companies. Longer clinical trials and regulatory review periods mean a shorter active patent life to recoup the investment. This also negatively impacts the innovator companies’ profitability. The twelve-year FDA exclusivity provided in the BPCIA might be justified as increasing the profitability of innovator companies (i.e., providing a long enough monopoly period so that innovator companies can recoup their investments and continue to innovate).

2. Patent Uncertainty

Patent uncertainty seriously affects the profitability of innovator drug companies. Generic drug companies are in an advantageous position in patent-invalidity challenges and have

84. Compare Grabowski, supra note 63, at 480 (showing that in oncology, the area with the greatest concentration of biological entities, the mean cost is “US$1.016 billion compared with $868 million” in small-molecule drugs), with DiMasi & Grabowski, supra note 76, at 477.

85. DiMasi & Grabowski, supra note 76, at 473; Grabowski, supra note 63, at 481.

86. Grabowski, supra note 63, at 481.

87. Id. at 482 (“This [higher development cost of biologics] reflects the need to resolve novel manufacturing challenges at the R&D stage. By contrast, manufacturing process issues in R&D are typically more straightforward for drugs based on chemical synthesis [i.e., small-molecule drugs].”).

88. Id.

89. Id. at 481–82. Because patent protection is a fixed term (i.e., twenty years from filing), the longer it takes for a drug to hit the market, the less patent term left to recoup the investment.


strong incentives to file such challenges.\textsuperscript{92} In addition, current developments in patent law make the invalidation of biotechnology-related patents especially easy.\textsuperscript{93} The twelve-year FDA exclusivity provides a complementary protection to this patent vulnerability, because FDA exclusivity is a monopoly power independent of patent protection.\textsuperscript{94} In other words, even if the patents covering the innovator drugs or biologics were invalidated, the granted FDA exclusivity is unaffected.

Recent Federal Circuit decisions further weaken the already vulnerable patents owned by innovator companies by imposing particularly stringent patent disclosure requirements.\textsuperscript{95} The Federal Circuit decisions imply that if a field of art is more predictive, such as mechanical engineering and software programming, less disclosure is required to fulfill the written description and enablement requirements.\textsuperscript{96} On the contrary, if the field of art is less predictive, such as chemistry or biotechnology, more disclosure is required.\textsuperscript{97} Recently, many

\begin{itemize}
\item \textsuperscript{92} See FTC, GENERIC DRUG ENTRY PRIOR TO PATENT EXPIRATION: AN FTC STUDY, at viii (2002), available at http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf ("[G]eneric applicants prevailed in nearly 75% of the patent litigation ultimately resolved by a court decision."); see also Higgins & Graham, supra note 91, at 370 (suggesting that generic companies have incentives to bring patent invalidity challenges, because the costs of challenging a patent are relatively small, i.e., "$5 million compared with the large average potential payoff of $60 million in the first 180 days alone").
\item \textsuperscript{93} See Dan L. Burk & Mark A. Lemley, Is Patent Law Technology-Specific?, 17 BERKELEY TECH. L.J. 1155, 1173–82 (2002) (noting that the Federal Circuit has adopted a particularly stringent disclosure standard for patenting macromolecules (i.e., biologics)). This heightened 35 U.S.C. § 112 "written description" requirement ends up becoming the legal ground for invalidating many biotechnology and chemical patents. \textit{Id.}
\item \textsuperscript{94} See Grabowski, supra note 63, at 480 (stating data exclusivity provides an important back-up to the patent system in cases where the patents could be invalidated).
\item \textsuperscript{95} See Burk & Lemley, supra note 93, at 1173 ("In contrast to the Federal Circuit decisions regarding software, recent decisions involving genetic material have imposed a stringent disclosure standard for patenting macromolecules.").
\item \textsuperscript{96} \textit{Id.} at 1157; e.g., N. Telecom, Inc. v. Datapoint Corp., 908 F.2d 931, 942 (Fed. Cir. 1990) ("The computer language is not a conjuration of some black art, it is simply a highly structured language . . . . [T]he conversion of a complete thought (as expressed in English and mathematics, i.e. the known input, the desired output, the mathematical expressions needed and the methods of using those expressions) into a language a machine understands is necessarily a mere clerical function to a skilled programmer.").
\item \textsuperscript{97} Burk & Lemley, supra note 93, at 1157.
\end{itemize}
biotechnology patents have been invalidated because of these stringent requirements. In addition, the safe harbor created by the Hatch-Waxman Act in patent law, 35 U.S.C. § 271, significantly strengthens generic companies’ legal positions in patent-invalidity challenges by creating an exemption for generic drug companies that conduct research on patent-protected reference drugs with the intention to gain FDA approval. This allows generic companies to gain thorough, hands-on knowledge regarding the targeted reference drugs and strengthens generic companies’ legal theories in patent-invalidity challenges.

98. E.g., Fiers v. Revel, 984 F.2d 1164, 1170–71 (Fed. Cir. 1993). The Federal Circuit invalidated a biologic patent, which disclosed methods for isolating a fragment of the DNA sequence coding for β-IF, a biologic, and for isolating messenger RNA coding for β-IF. Id. at 1167, 1170. The invalidation was largely based on the fact that Revel did not describe the actual sequence of the DNA at issue, id. at 1170–71, even if transferring an RNA sequence to DNA sequence is considered merely a mechanical routine that involves no technical challenge. See Reverse Transcriptase Enzymes, LIFE TECHNOLOGIES, http://www.lifetechnologies.com/us/en/home/life-science/pcr/reverse-transcription/reverse-transcriptase-enzymes.html (last visited Sept. 15, 2013) (listing an enzyme cost per reaction as low as $1.15); see also Regents of the Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559, 1575 (Fed. Cir. 1997). The Federal Circuit invalidated a patent which claimed human insulin DNA but only disclosed rat insulin DNA, id. at 1567–68, disregarding that the research methods used in sequencing rat and human are exactly the same and that rat and human DNA sequences are 95% identical. See Nonconfidential Brief for Defendant-Appellee Eli Lilly & Co. at 43, Regents of the Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559 (Fed. Cir. 1997) (No. 96-1175), 1996 WL 33419502 (“The trial evidence established that a change in only four nucleotides of the rat DNA sequence would have yielded a sequence capable of producing human insulin.”).


It shall not be an act of infringement to make, use, offer to sell, or sell within the United States or import into the United States a patented invention . . . solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs or veterinary biological products.

Id. (emphasis added). It should be noted that this safe harbor provision language is general and covers both small-molecule drugs and biologics.

Generic drug companies have strong incentives to challenge innovator companies’ patents. The Hatch-Waxman Act provides five-year data exclusivity to new chemical entities, during which generic drug companies cannot submit an ANDA referring to the patented drug’s clinical data. However, there is an exception that can shorten data exclusivity by one year. An ANDA can be submitted at the end of the fourth year if the ANDA is submitted under 21 U.S.C. § 355(j)(5)(B)(iv), which commences a patent-invalidation challenge. The first approved generic drug submitted under Paragraph IV is entitled to 180-day market exclusivity. During this market exclusivity period, the FDA will not approve another ANDA application (i.e., during this 180 days, the successful challenger’s generic drug will be the only generic drug on the market). This 180-day market exclusivity provides generic drug companies with strong incentives to challenge innovator drug patents. Indeed, patent-invalidation challenges commenced under Paragraph IV ANDA submissions generally increased in the past decade. The BPCIA provides similar mechanisms for FOB companies to raise patent-invalidation

101. See Higgins & Graham, supra note 91, at 370 (suggesting generic companies have an incentive to bring patent-invalidity challenges).

102. 21 U.S.C. § 355(c)(3)(E)(ii) (2012). The statute provides: [N]o application [i.e., ANDA] ... may be submitted ... before the expiration of five years from the date of the approval of the application under subsection (b) of this section [i.e., the approved reference drug], except that such an application [i.e., ANDA] may be submitted under subsection (b) of this section after the expiration of four years from the date of the approval of the subsection (b) application if it contains a certification of patent invalidity or noninfringement described in clause (iv) of subsection (b)(2)(A) of this section [i.e., paragraph IV challenge].

Id. (emphasis added). In sum, that statute specifically prevents a generic company from submitting an ANDA during the five-year data exclusivity period.

103. § 355(b)(2)(A)(iv). An ANDA submitted under § 355(b)(2)(A)(iv), also known as a Paragraph IV submission, includes a patent-invalidation challenge. Higgins & Graham, supra note 93, at 370. This provision states: “such patent is invalid or will not be infringed by the manufacture, use, or sale of the new drug for which the application is submitted.” § 355(b)(2)(A)(iv).

104. § 355(j)(5)(B)(iv).

105. § 355(j)(5)(B)(iv)(I). This provision incentivizes generic companies to challenge weak patents. See FTC, supra note 92.


107. See FTC, supra note 92.

challenges. This ever-increasing number of patent-invalidation challenges denotes that innovator drug companies suffer a high level of patent uncertainty, which drastically decreases the profitability of innovator drugs. Fosamax, a popular osteoporosis drug made by Merck that generates $3 billion in annual sales, illustrates clearly the serious economic damages caused by patent uncertainty. Teva, the largest generic drug company in the world, brought an invalidation challenge under Paragraph IV and successfully invalidated Fosamax patents about four years before they were due to expire. Fosamax’s sales drastically decreased in the subsequent year of 2008 from $3 billion to $1.5 billion. In addition, Teva alone had 160 pending ANDAs in 2007, including 92 Paragraph IV challenges, which put at risk over $100 billion in sales.

The Federal Trade Commission (FTC) reported that generic companies prevailed in 75% of patent-invalidation challenges, while the challenge success rate across all technical fields was at 52%. This patent uncertainty seriously affects innovator drug companies’ ability to fund the

---


[An ABLA] applicant [e.g., an FOB company] shall provide to the reference product sponsor [i.e., innovator company] . . . a detailed statement that describes, on a claim by claim basis, the factual and legal basis of the opinion of the subsection (k) applicant [i.e., the FOB company] that such patent is invalid, unenforceable, or will not be infringed by the commercial marketing of the biological product that is the subject of the subsection (k) application.

_id_.

110. Higgins & Graham, _supra_ note 91, at 370.

111. _Id_. at 370–71.


114. _Id_.

115. _Id_.

116. _See_ FTC, _supra_ note 92.

117. PRICewaterHOUSEcOOPERS, _A Closer Look: 2008 Patent Litigation Study: Damages Awards, Success Rates and Time-to-Trial_ 10 (2008), _available at_ http://www.pwc.com/en_us/us/forensic-services/assets/2008_patien_litigation_study.pdf. The PricewaterhouseCoopers report shows that, across all technical fields, 52% of the patent invalidations in which the alleged infringer is the plaintiff are successful. In contrast, the FTC reported that 75% of litigated biotechnology patents are declared invalid. This suggests that biotech patents are particularly vulnerable to patent-invalidity challenges.
research for new drugs. Many commentators argue that extended FDA exclusivity is necessary to promote innovation because it is independent from patent exclusivity and stays effective regardless of the validity of the covering patents.

3. Decrease in New Drug Applications

The annual number of new drug applications generally decreased in the past fifteen years, despite significant development in biological science and technology.

Science and technology in the biomedical field has hugely advanced in the past sixty years. For example, during the 1980s to 1990s, the number of drug candidates that could be synthesized by an individual chemist in a year increased 800-fold. The speed of DNA sequencing increased a billion times since 1970. The time required to deduce a protein structure via X-ray diffraction decreased more than a thousand times.

Despite the advancement of technology, the number of new drugs approved per $1 billion spent on research and development has decreased by half every nine years since 1950. This rate of decrease falls short roughly eighty-fold in inflation-adjusted terms. The average number of new drugs approved each year between 1995 and 1999 was 37.6. The number decreased to 30.0 during 2000–2004, and the number dropped to 20.2 during 2005–2009.

118. See Higgins & Graham, supra note 91, at 371 (“Economic research shows that there is a [pharmaceutical] market failure . . .”).

119. Id. at 371; see also Grabowski, supra note 63, at 479. Contrary to the uncertainty inherent in the patent system, FDA exclusivity provides a defined period of monopoly with absolute certainty.


122. Id.

123. Id.

124. Id.

125. Id.

126. Id.

127. Id.

Commentators have suggested many possible reasons that explain the constant decrease of innovation in the pharmaceutical industry. One explanation is that in vitro experiments conducted in the laboratory are not necessarily repeatable in humans, meaning the basic research is performed without benefiting the medical industry. Another explanation is the “low-hanging fruit” theory: fruit that hangs lower will get picked first. This is saying the relatively easier medical problems have been solved earlier, and what remains today are issues that are more difficult. Another explanation is it is harder to develop a better new drug. If a new drug is not better than existing therapies, the drug will likely be abandoned because the marginal profit does not justify the investments.

The explanations provided by commentators are speculative in nature and hard to verify. However, it is a fact that the number of approved new drugs has decreased steadily in the past two decades. This steady decrease in innovation may justify twelve-year FDA exclusivity that provides a longer period of market monopoly and a higher profit margin for innovator drug companies.

129. E.g., Scannell et al., supra note 121, at 193–97. Scannell et al. introduced several different theories to explain the drop in innovation, including: the “better than the Beatles” problem, the “cautious regulator” problem, the “throw money at it” tendency, and the “basic research brute-force” bias. Id. at 193. Yet Scannell et al. admit that none of the theories are conclusive.


131. Id. at 151.

132. See Scannell et al., supra note 121, at 193 (“An ever-improving back catalogue of approved medicines increases the complexity of the development process for new drugs, and raises the evidential hurdles for approval, adoption and reimbursement.”).

133. Id. (“[T]he fruit [the authors’ metaphor for pharmaceutical drugs] that has been picked reduces the [average] value of the fruit that is left in the tree.”).

134. See id. at 198. By suggesting possible reasons to explain the steady decrease in new drug applications, Scannell et al. wanted to “provoke further analysis.”


137. Cf. Higgins & Graham, supra note 91, at 371 (“A robust system of market innovation is built on financial incentives.”).
B. PROMOTING ACCESSIBILITY

New biologics promise cutting edge therapies for the toughest diseases faced in our time.\textsuperscript{138} However, there will be no meaningful benefit to society if these therapies are prohibitively expensive and not accessible to the general public.\textsuperscript{139}

Unfortunately, many biologic therapies are prohibitively expensive.\textsuperscript{140} Biologics on average cost twenty times more than small-molecule drugs.\textsuperscript{141} For example, Enbrel, an anti-arthritis biologic, costs $20,000 per year, compared to $300 per year for the most expensive small-molecule drug treatment for arthritis.\textsuperscript{142} Treating breast cancer with a year’s worth of the biologic Herceptin can cost $48,000.\textsuperscript{143} Remicade, a biologic treatment for rheumatoid arthritis costs $20,000 a year.\textsuperscript{144} Cerezyme, a treatment for a rare genetic disorder, Gaucher disease, which causes fatty deposits to build up in certain organs and bones, costs $200,000 to $300,000 per year.\textsuperscript{145} From 1998 to 2006, the overall costs for biologics went up 505\%, according to Kaiser Permanente.\textsuperscript{146} The overall sales of biologics reached around $100 billion in 2010, representing 26\% of the total cost of pharmaceuticals.\textsuperscript{147}

The ABLA aims to replicate the successful experience of ANDA to lower the drug price by introducing market

\begin{footnotesize}
\begin{itemize}
\item[138.] See Patton, supra note 32 (stating that biologics are the “wonder drugs” of our age because they promise to treat AIDS, cancer, Alzheimer’s, and multiple sclerosis).
\item[139.] Victoria Colliver, Priced Out of Pain Relief: Insurers Balk at High Costs of Promising New Treatments, S.F. CHRON., May 8, 2007, at C1 (stating that insurance companies balk at covering the full price of biologic therapies because they are too expensive).
\item[140.] Patton, supra note 32 (“From 1998 to 2006, the costs of [biologic drugs] shot up 505 percent . . . .”).
\item[141.] Karen Tumulty & Michael Scherer, You Don’t Know Him (He’s a Lobbyist) but He May Be the Biggest Winner in Health-Care Reform. So Who Loses?, TIME, Nov. 2, 2009, at 38, available at http://www.time.com/time/magazine/article/0,9171,1931729,00.html.
\item[142.] Patton, supra note 32.
\item[143.] Tumulty & Scherer, supra note 141, at 38.
\item[144.] Id.
\item[146.] Patton, supra note 32.
\item[147.] Roth, supra note 29, at 6.
\end{itemize}
\end{footnotesize}
competition. However, the ABLA faces distinct challenges that may hinder the purpose to promote accessibility. Part II.B explores four aspects of these challenges: complexity and delicacy of biologics, statutory and administrative ambiguity, excessively long FDA exclusivity, and evergreening.

1. The Complexity and Delicacy of Biologics

Many commentators opine that it is scientifically impossible to produce a bioequivalent generic biologic, as in generic small-molecule drugs, due to the natural complexity and delicacy of biologics. Biologic products are extremely sensitive to environmental conditions. Any minor change in the manufacturing process, such as temperature, water quality, or even external packaging, can change the overall safety and efficacy of biologics.

The story of Eprex highlights the extreme delicacy of biologics and the difficulties in making FOBs. Eprex, made by Janssen-Cilag, is an FOB of Epogen, made by Amgen. Eprex, like Epogen, treats chronic kidney disease patients for aplasia. In 1998, incidence of pure red-cell aplasia, a rare disorder that manifests as a severe, sudden-onset anemia with complete absence of red blood cell precursors in the bone marrow, were noticed among the patients receiving Eprex. The uncommon scenario was that the incidents happened in patients receiving Eprex in Europe, but not in the United

148. Tzeng, supra note 68, at 135.
149. E.g., Park et al., supra note 79, at 1688–89. Many scientists believe that it is impossible to produce a generic biologic that is bioequivalent and bioavailable as the referenced biologic. This is the reason why the scientific communities use the term “follow-on biologics” instead of “generic biologics.”
151. Id.; see also JUDITH A. JOHNSON, CONG. RESEARCH SERV., FDA REGULATION OF FOLLOW-ON BIOLOGICS, at i (2010) (“Biologics often require special handling (such as refrigeration) and are usually administered to patients via injection or infused directly into the bloodstream.”).
153. Id.
155. Boven et al., supra note 152, at 2346.
156. Id.
The reason turned out to be that the medical facilities in Europe administered Eprex using syringes with *uncoated* rubber stoppers instead of coated ones. The uncoated rubber stopper releases certain organic compounds that cause coagulation of the active proteins that induce increased immunogenicity. The whole incident highlights the natural delicacy of biologics, showing that even a minor change in the delivery equipment (e.g., rubber stopper), could be lethal. Commentators argue that this natural delicacy of biologics potentially renders the interchangeability of the FOB—the idea that the FOB can be substituted by a pharmacist without consulting medical doctors—impracticable.

2. Statutory and Administrative Ambiguity

The BPCIA has been enacted, but the statutory interpretation and administrative implementation are far from definite. Particularly, whether the twelve-year FDA exclusivity is a *data* or *market* exclusivity is still under debate. The provision of “exclusivity for reference product” of the BPCIA states:

(A) Effective date of biosimilar application approval

Approval of an application [i.e., ABLA] under this subsection may not be made effective by the Secretary until the date that is 12 years after the date on which the reference product was first licensed under subsection (a).

(B) Filing period

---

157. *Id.*

158. *Id.* at 2346–47.

159. *See id.* at 2352 (“[T]he evidence of [syringes with uncoated rubber stoppers’] capacity to increase the immunogenicity in experimental animals [ ] suggest[s] that [the organic compounds] were the critical contributory factor in the increased incidence of antibody mediated PRCA attributed to Eprex.”).

160. *Id.* at 2346–47.

161. *E.g.*, Jonathan Stroud, *The Illusion of Interchangeability: The Benefits and Dangers of Guidance-Plus Rulemaking in the FDA’s Biosimilar Approval Process*, 63 ADMIN. L. REV. 599, 618 (2011). As of the time this Note was written, the FDA had not approved any FOB through ABLA.


163. *Id.*
An application under this subsection may not be submitted to the Secretary until the date that is 4 years after the date on which the reference product was first licensed under subsection (a). 164

The four-year exclusivity in (B) is generally interpreted to be data exclusivity because the statutory language matches the definition of data exclusivity (i.e., the FDA will not accept any filing of an ABLA until four years after the reference biologic is approved because FOB manufacturers are precluded from relying on innovator data). 165 The debate focuses on whether the twelve-year exclusivity provided in (A) is market or data exclusivity. 166

The FDA, on October 5, 2010, interpreted the twelve-year exclusivity in (A) as a market exclusivity. 167 This is a reasonable interpretation for two reasons. First, the statutory language is: “Approval of an application under this subsection may not be made effective . . . until the date that is 12 years after the date on which the reference product was first licensed” matches the general understanding of market exclusivity (i.e., the FDA can accept and review an ABLA but will not approve it until the twelve-year market exclusivity expires). 168 Second, reading (A) as data exclusivity renders (B) superfluous. 169 However, Senators Hagan, Hatch, Enzi, and Kerry, 170 and Representatives Eshoo, Inslee, and Barton 171

168. Karst, supra note 49.
169. If (A) were a data exclusivity period then (B) would be superfluous, because a twelve-year period certainly covers a four-year period. In other words, if (A) is a data exclusivity period then (B) has no effect.
170. Letter from Senators Kay R. Hagan, Orrin Hatch, Michael Enzi, and John F. Kerry, U.S. Senate, to Dr. Margaret Hamburg, Comm’r of Food and Drug Admin. (Jan. 7, 2011) [hereinafter Letter from Senators], available at http://www.hpm.com/pdf/1-7-11%20Senate%20Biologics%20letter%20to%20FDA.pdf (clarifying that the BPCIA does not provide market exclusivity, but provides data exclusivity); see also Dorn, supra note 162.
responded to the FDA’s interpretation, clarifying that § 262(k)(7)(A) is a data exclusivity.

The difference between data or market exclusivity is significant; it means three to four years of delay in introducing FOB competition and tens of billions of dollars to the general public.172 The delay is the time for conducting clinical trials and FDA regulatory reviews.173 According to FDA guidance documents, ABLA applicants will generally be required to conduct a certain scale of clinical trials to show biosimilarity or interchangeability.174 After the clinical trials are completed, the regulatory review phase for the FDA to approve a biologic takes about sixteen months.175 In the case that the twelve-year exclusivity is data exclusivity, an FOB manufacturer will have

pdf/EIB%20Ltr%20FDA%20DEC%202010.pdf (clarifying the twelve-year exclusivity is a data exclusivity); see Dorn, supra note 162.

172. For reasons why ABLA is expected to take, on average, three to four years (including clinical trial phase and regulatory review phase) to be approved, see Trends in NDA and BLA Submissions and Approval Times, FOOD & DRUG ADMIN., http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/PerformanceReports/PDUFA/ucm209349.htm (last updated May 4, 2010).

173. Clinical trial and regulatory review are two different time periods. An innovator drug company submits an investigational new drug (IND) application to conduct the clinical trials. After the clinical trials are completed, the innovator company then submits a new drug application (NDA) to start the formal regulatory review process. See Running Clinical Trials, FOOD & DRUG ADMIN., http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/ucm155713.htm (last updated Mar. 20, 2013) (listing the regulations governing clinical trials and regulatory reviews).

174. FDA, BIOSIMILARS: QUESTIONS AND ANSWERS REGARDING IMPLEMENTATION OF THE BIOLOGICS PRICE COMPETITION AND INNOVATION ACT OF 2009, at 8–12 (2012) [hereinafter BIOSIMILARS: QUESTIONS AND ANSWERS], available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM273001.pdf (noting that to demonstrate biosimilarity, an ABLA applicant has to conduct rigorous structural and functional comparisons showing minimal or no difference between the FOB and the referenced biologic (e.g., bench/lab tests); then, the ABLA applicant should produce comparative human clinical trial data showing human pharmaceutical kinetic (PK), pharmaceutical dynamic (PD), and immunogenicity studies in an “appropriate population”). This shows that the FDA will certainly require a level of clinical trials appropriate to the biologic. See also Makiko Kitamura & David Wainer, Biosimilars Lure Major Drugmakers into the Generics Biz, BLOOMBERG BUSINESSWEEK (Mar. 21, 2013), http://www.businessweek.com/articles/2013-03-21/biosimilars-lure-major-drugmakers-into-the-generics-biz (noting FOB companies might have to do even more clinical trials than those required by the FDA to convince skeptical medical practitioners to use their FOBs—“life-and-death drugs”).

175. Grabowski, supra note 63, at 481 (showing in Figure 1 that the regulatory review period for biologics takes an average of sixteen months).
to submit an ABLA after twelve years and take another three to four years to go through the clinical trials and regulatory review process.\textsuperscript{176} This de facto extends the monopoly period enjoyed by the innovator biologic manufacturers beyond twelve years. Whereas, if (A) were market exclusivity and (B) were data exclusivity, an ABLA could be submitted four years after the reference biologic was approved, and it could likely go through clinical trials and regulatory reviews before the twelve-year data exclusivity expired.\textsuperscript{177} Consequently, the FOB could be on the market the very day the twelve-year market exclusivity expires.

Besides statutory ambiguity, the FDA regulations to implement the ABLA are also not clear. The FDA has ten years from the enactment of the BPCIA to finalize the regulatory structure of abbreviated biological license application, meaning the implementation standards are unlikely to be finalized until 2020.\textsuperscript{178} On February 9, 2012, the FDA released three draft guidance documents that shed some light on the implementation of ABLA: (1) Scientific Considerations in Demonstrating Biosimilarity to a Reference Product;\textsuperscript{179} (2) Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product: Biosimilars;\textsuperscript{180} and (3) Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009.\textsuperscript{181} The documents highlight that, in approving an FOB, the FDA will make a case-by-case determination, examining the totality of the evidence.\textsuperscript{182} In view of the natural delicacy and complexity

\textsuperscript{176} See Karst, supra note 49 (stating that generic supporters argue that interpreting the twelve-year FDA exclusivity as a data exclusivity, which prevents biosimilar (i.e., ABLA) submissions, has serious consequences and that consumers will have to endure an indeterminate delay of FDA review and approval that could extend “far beyond the 12-year total that was set in the legislation”).

\textsuperscript{177} Cf. Bagley, supra note 48, at 15–18 (explaining market exclusivity within the context of pediatric testing exclusivity and orphan drug exclusivity).

\textsuperscript{178} Stroud, supra note 161, at 620.

\textsuperscript{179} SCIENTIFIC CONSIDERATIONS, supra note 77.


\textsuperscript{181} BIOSIMILARS: QUESTIONS AND ANSWERS, supra note 174.

\textsuperscript{182} SCIENTIFIC CONSIDERATIONS, supra note 77, at 2; see also Steven Kozlowski et al., Developing the Nation’s Biosimilars Program, 365 NEW ENG. J. MED. 385, 386 (2011).
of biologics, additional animal and clinical studies will generally be required.\textsuperscript{183} However, the scope and extent of such studies can be reduced if more extensive, fingerprint-like analyses are provided.\textsuperscript{184} Immunogenicity is considered a critical risk factor in assessing biosimilarity.\textsuperscript{185} The FDA is aware that pharmaceutical companies often make changes to the manufacturing process.\textsuperscript{186} The FDA will continuously monitor the quality of FOBs in regard to those changes.\textsuperscript{187} A biologic will be considered interchangeable with a reference product if the developer demonstrates similar clinical results in all types of patients, and the risk associated with switching between the two biologics is not greater than continuously using the reference biologic.\textsuperscript{188}

3. Excessively Long FDA Exclusivity

The history of the Hatch-Waxman Act shows that the patent-invalidation challenge is an important mechanism to increase drug price competition.\textsuperscript{189} However, the twelve-year FDA exclusivity in the BPCIA, regardless of whether it is a data or market exclusivity, arguably vacates the incentives to challenge biological patents.\textsuperscript{190} This is because FDA exclusivity

\begin{itemize}
\item \textsuperscript{183} \textsc{Scientific Considerations, supra} note 77, at 10–19.
\item \textsuperscript{184} \textit{Id.} at 7.
\item \textsuperscript{185} \textit{Id.} at 7–10.
\item \textsuperscript{186} \textit{See Quality Considerations, supra} note 180, at 3 (“Since 1996, FDA has approved many manufacturing process changes for licensed biological products, based on a demonstration of product comparability before and after the process change, as supported by quality criteria and analytical testing and without the need for additional nonclinical data and clinical safety and/or efficacy studies.”).
\item \textsuperscript{187} \textit{Id.} at 4 (stating that if the reference product and the proposed protein product cannot be adequately characterized, the FDA recommends that the sponsor consult the FDA for guidance).
\item \textsuperscript{188} \textit{Id.} at 4.
\item \textsuperscript{189} \textit{See} Higgins & Graham, \textit{supra} note 91, at 370 (noting patent invalidity challenges brought by generic companies cut down brand-name companies’ profit significantly).
\item \textsuperscript{190} \textit{See} Engelberg et al., \textit{supra} note 145, at 1917 (noting that the Biosimilar Act guarantees innovator drug companies twelve years of market exclusivity for a new biologic agent before any biosimilar product could be approved, even in the absence of a valid patent); \textit{see also} Tzeng, \textit{supra} note 68, at 156 (stating that the twelve-year data exclusivity runs potentially longer than patent protection and demonstrating that this twelve-year exclusivity destroys the incentives for generic drug companies to bring patent-invalidity challenges because even if the underlying patents are invalidated, the FOB still has to wait for the twelve-year FDA exclusivity to expire to hit the market). In addition, because this twelve-year period is likely to last longer
remains effective even if the patents covering the reference biologics are invalidated and a twelve-year period after FDA approval is likely to run longer than the underlying patents.\textsuperscript{191}

This twelve-year FDA exclusivity is likely to live longer than the remaining active patent term.\textsuperscript{192} Active patent term refers to the overall patent life minus the overall administration time spent in the United States Patent and Trademark Office (USPTO) and the FDA.\textsuperscript{193} The overall patent life is the summation of twenty years from filing, the patent term adjustment (PTA) granted by the USPTO, and the patent term extension (PTE) granted by the FDA.\textsuperscript{194} Put simply, PTA is granted if USPTO examination took more than three years from filing to issuance.\textsuperscript{195} The examination time in excess of three years will be granted as PTA.\textsuperscript{196} On average, the USPTO takes 33.7 months to review a patent application, slightly short of three years.\textsuperscript{197} Thus, PTA is likely to be zero. The period of PTE granted by the FDA is calculated by adding one-half of the time during which the drug is evaluated as an “investigational new drug” to the time the drug is pending approval at the FDA.\textsuperscript{198} However, the extension cannot exceed a maximum than the remaining patent life, there is no point for generic drug companies to spend the litigation resources to invalidate the underlying patents.

\textsuperscript{191} Engelberg et al., \textit{supra} note 145, at 1917.
\textsuperscript{192} See Tzeng, \textit{supra} note 68, at 156 (stating that the twelve-year data exclusivity runs potentially longer than patent protection). I use the term “active patent term” to mean the patent period that the drug is actually on the market and generating revenue for the patentee. This active patent term is the overall patent life minus overall administration time. Overall patent life means the regular twenty years from filing, plus patent term adjustment, plus patent term extension. Overall administration time is the time spent in the U.S. Patent and Trademark Office to secure the patent and the FDA to get the drug approved.
\textsuperscript{193} \textit{Id.}
\textsuperscript{194} \textit{Id.}
\textsuperscript{195} 35 U.S.C. § 154(b) (2006 & Supp. V 2011) (guaranteeing prompt patent and trademark office responses and specifying the conditions of granting patent term adjustments); see also Bagley, \textit{supra} note 48, at 11 (“[T]he USPTO is expected to take no more than three years to examine and issue a patent on an application. If the USPTO fails to issue a patent within three years from the actual U.S. filing date, it must extend the term of the resulting patent one day for each day beyond the three-year period until the patent issues.”).
\textsuperscript{196} See Bagley, \textit{supra} note 48, at 11.
period of five years,\(^{199}\) nor can it extend patent expiration to a
date more than fourteen years after being approved by the
FDA.\(^{200}\) The average PTE awarded by the FDA in approving a
new drug is 43.2 months.\(^{201}\) The FDA takes an average of 110
months to approve an innovator biologic, counting both the
clinical phase and the regulatory review phase.\(^{202}\)

Thus, the average active patent term for a new biologic is
(in months): 240 (20 years from filing) + 0 (patent term
adjustment) + 43.2 (PTE) – 33.7 (PTO examination time) – 110
(FDA approval time) = 139.5 months (11.65 years). Therefore, it
is more likely than not that the patents covering innovator
biologics will expire before the twelve-year FDA exclusivity
expires.\(^{203}\)

In light of all the characteristics of this twelve-year FDA
exclusivity (independent from and likely to last longer than the
underlying patents), there is little to no incentive for FOB
companies to challenge the patents.\(^{204}\) President Obama
expressed his concern that the twelve-year FDA exclusivity tips
the balance toward innovator drug companies and proposed to
reduce it to seven years.\(^{205}\) Commentators even speculate that,

---

199. § 156(g)(6)(A).
200. § 156(c)(3).
201. Charles Clift, *The Value of Patent Term Extensions to the*
     *Pharmaceutical Industry in the USA*, 5 J. GENERIC MED. 201, 205 (2008)
     (showing that the average PTE awarded to the forty best selling drugs in 2006
     was 43.2 months).
202. See Grabowski, supra note 63, at 481–82 (showing that, on average,
     standard NCE/BLA applications take 110 months to be approved). An
     innovator biologic (i.e., BLA) takes on average 110 months to be approved,
     including both the time of clinical trial and regulatory review.
203. See Tzeng, *supra* note 68, at 156.
204. See Engelberg et al., *supra* note 145, at 1919 (noting that a rigid
     twelve-year exclusivity period essentially eliminates the need for innovator
     companies to defend any patents).
205. See Mike Palmedo, *Obama’s Deficit Plan Would Reduce Data*
     *Exclusivity for Biologics and Ban Pay-for-Delay Patent Settlements,*
     (“[The Obama administration’s] proposal would reduce data exclusivity for biologic
     medicines to 7 years . . . and would ‘prohibit additional periods of exclusivity
     for brand biologics due [to] minor changes in product formulations, a practice
     often referred to as “evergreening.”’ The administration predicts that the
     shorter periods of data exclusivity will ‘encourage faster development of
     generic biologics while retaining appropriate incentives for research and
development for the innovation of breakthrough products.’”); see also Dorn,
     *supra* note 162; Andrew Pollack, *Obama Pushes More Competition on Biologic*
     *Drugs*, N.Y. TIMES, Sept. 19, 2011, available at
in view of this excessively long twelve-year exclusivity, the ABLA pathway will not be used much because FOB companies will likely ignore ABLAs and file regular Biologics License Applications (BLAs), thus avoiding the delay of the twelve-year period.206 This creates a lose-lose-lose situation for the FOB companies, the innovator companies, and the general public, because FOB companies will not be able to save cost by relying on innovators’ clinical data, nor will the innovator drug company get to enjoy the full twelve-year exclusivity, nor will the general public enjoy the drug price competition.207

4. Evergreening

Evergreening strategy refers to patenting activities by innovator drug companies on ancillary aspects of the drugs.208 The natural complexity of biologics provides convenient mechanisms for innovator drug companies to engage in evergreening, such as reformulation of drugs, new manufacturing processes, or quality-control methodologies.209


206. See Engelberg et al., supra note 145, at 1918 (“[M]anufacturers of potential follow-on products would probably prefer to ignore the new pathway and opt to file a standard BLA, which would not be subject to the 12-year delay. Any higher cost would be offset by the greater profit opportunity available to early market entrants. Therefore, as currently fashioned, the biosimilar legislation would have no value, because it would create a pathway that would scarcely be used. Innovators would not get the benefit of the exclusivity provision, and the public would not get the benefit of the enhanced price competition that would result from increasing the number of competitors.”).

207. Id. Engelberg speculates that the twelve-year FDA exclusivity creates a lose-lose-lose situation among the innovator company, FOB company, and the general public. Innovator companies will not enjoy the twelve-year exclusivity because FOB companies will design around and go through regular BLA to avoid the delay of the twelve-year period. FOB companies will not be able to enjoy the cost-saving, fast track ABLA because regular BLA is preferred. The general public will not be able to enjoy low price biologics because FOB companies will have to price higher in order to recoup the investment for going through regular BLA.

208. See Hemphill & Sampat, supra note 66, at 327–28 (describing evergreening as securing or acquiring patents on ancillary aspects with doubtful validity in order to delay generic competition).

209. See Christopher Weaver et al., Biotech Drugs Still Won’t Copy, WALL ST. J., Feb. 27, 2013, at B1 (noting that innovator biologic companies can gain patents on manufacturing procedures and formulations to extend the market monopoly period). The CEO of AbbVie Inc., a spin-off of Abbott Laboratories, said that AbbVie has more than 200 such patents on Humira, an innovator biologic treating arthritis. Id.
For example, an innovator biologic company can secure a patent on a reformulation of a biologic, improving certain peripheral effects. Then, right before the expiration of the twelve-year exclusivity, the innovator drug company can obtain a quick approval of the reformulated biologic by referring to its own clinical data and enjoy a renewed twelve-year monopoly.

The evergreening issue was debated in Congress. Senator Orrin Hatch and Senator Kay Hagan sent a letter on January 7, 2011 calling on the FDA to interpret the BPCIA such that innovator drug companies should get a renewed twelve years of exclusivity if manufacturers alter an existing product to improve safety or potency. Senator Sherrod Brown and proponents of generic companies disagreed with this interpretation and showed great concerns that this tweak-to-renew tactic would increase costs for consumers, businesses, and taxpayers. President Obama also expressed his intention to prohibit evergreening. Siding with the President, Pamela Jones Harbour, the then Commissioner of the FTC, expressed her opinion in June of 2009: “no additional period of branded exclusivity is needed to spur the development of new drug products” because pioneer biologics are already covered by varied patents and market-based exclusivities, providing strong incentives to innovate.

210. See Alicia Mundy, Biotech Firms Fight Generics, WALL ST. J., Jan. 12, 2011, http://online.wsj.com/article/SB1000142405274870388920457607825226 0327210.html (noting that Senators Hatch and Hagan stated in a letter to the FDA that companies should get an additional twelve years of exclusivity if an existing product is altered to improve safety or potency).

211. Id. Note that the twelve-year exclusivity excludes follow-on competitors but not the original data owner.

212. Id.

213. Letter from Senators, supra note 170 (“If a manufacturer modifies an approved product to produce a change in safety, purity or potency, the modified product is rightly considered a new product. It will be protected by the data exclusivity provisions afforded new products. Exclusivity on the first generation product will expire as scheduled.”).

214. See Mundy, supra note 210.

215. See Palmedo, supra note 205 (noting that the Obama administration proposes to prohibit additional periods of exclusivity for brand biologics due to minor changes in product formulations, a practice often referred to as “evergreening”).

A recent case in 2012, Momenta Pharmaceuticals, Inc. v. Amphastar Pharmaceuticals, Inc., provides an example of evergreening in therapies that require a high level of quality control, such as biologics.\textsuperscript{217} Momenta Pharmaceuticals (Momenta) and Amphastar Pharmaceuticals (Amphastar) are both generic drug companies making generic versions of Lovenox (enoxaparin), produced by Aventis Pharmaceuticals.\textsuperscript{218} Enoxaparin requires a high level of continuous quality control.\textsuperscript{219} In order to ensure quality, the FDA required both Momenta and Amphastar to profile their products via mass spectroscopy, nuclear magnetic resonance spectroscopy, modifying reagents, or modifying enzymes, to show their enoxaparin is equivalent to Lovenox.\textsuperscript{220} Amphastar was the first to be approved by the FDA.\textsuperscript{221} However, Momenta owns a method patent (Patent No. 7,575,886, “the ‘866 patent”) in quality control (i.e., an evergreening patent) to show its product is equivalent to Lovenox.\textsuperscript{222} Before Amphastar’s enoxaparin could reach the market, Momenta asserted infringement actions alleging that Amphastar inevitably infringed its ‘866 patent.\textsuperscript{223} Amphastar’s enoxaparin eventually reached the market after Momenta.\textsuperscript{224} This scenario highlights an evergreening strategy: a quality-control patent can conveniently be used to extend a market monopoly in therapies

\footnotesize
\begin{itemize}
  \item \textsuperscript{217} Momenta Pharm., Inc. v. Amphastar Pharm., Inc., 686 F.3d 1348, 1349–52 (Fed. Cir. 2012).
  \item \textsuperscript{218} Id.
  \item \textsuperscript{219} Id. at 1349–50.
  \item \textsuperscript{220} Id. at 1350–51.
  \item \textsuperscript{221} Id. at 1351.
  \item \textsuperscript{222} Id.
  \item \textsuperscript{223} Id.
  \item \textsuperscript{224} Id. at 1351–62. The majority ruled against Momenta in \textit{Momenta v. Amphastar}. Judges Moore and Dyk reasoned that even if Amphastar infringed Momenta’s profiling method, patent ‘866, it was exempted under the safe harbor (35 U.S.C. § 271(e)(1)) because the quality control and profiling of the product falls within the statutory language: “reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use or sale of drugs . . . .” Id. at 1357–59. The majority ruling partially answers the concern of using quality-control and product-profiling patents to extend market monopoly. However, Judge Rader dissented, arguing that the safe harbor should be limited to \textit{pre-approval} activities. Id. at 1361–76 (Rader, J., dissenting). If Judge Rader’s point of view subsequently prevails, the activities of continuous quality-controlling and profiling after an FOB is approved will constitute patent infringement. In other words, brand-name companies can assert quality control method patents to deter FOBs.
\end{itemize}
that require continuous, high-quality monitoring, such as biologics.\textsuperscript{225}

C. BIOSIMILAR—A GAME OF BRAND-NAME COMPANIES

Maybe the wrestling between the proponents for innovators and FOB companies will eventually be moot because the biosimilar game is likely among brand-name companies.\textsuperscript{226} In 2009, the FTC stated the following in one report:

FOB products are likely to take eight to ten years to develop, and their development will likely cost between $100 and $200 million. These amounts differ substantially from the product development costs for small-molecule generic drugs, which typically take three to five years to develop and cost between $1 and $5 million.\textsuperscript{227}

In light of the high cost to enter the market, the dynamics of biosimilar competition will likely be “brand-name to brand-name,” rather than “brand-name to generic” competition.\textsuperscript{228} Indeed, Merck and Pfizer, both recognized as brand-name companies, have started to develop FOBs referencing Amgen and Roche’s biologic products.\textsuperscript{229}

\textsuperscript{225} See Weaver et al., \textit{supra} note 209 (stating that Merck retreated from a plan to develop an FOB of Enbrel, an innovator biologic made by Amgen, because Amgen recently gained a new patent on Enbrel).

\textsuperscript{226} See Kitamura & Wainer, \textit{supra} note 174 (noting it would take about $100 to $200 million to develop an FOB, much higher than the $50 million needed to make a generic small-molecule drug). The higher threshold makes biosimilar development likely to be a game among big pharmaceutical companies. \textit{Id}.

\textsuperscript{227} FTC, \textit{EMERGING HEALTH CARE ISSUES: FOLLOW-ON BIOLOGIC DRUG COMPETITION} 6 (2009) [hereinafter \textit{EMERGING HEALTH CARE ISSUES}], available at \url{http://www.ftc.gov/os/2009/06/P083901biologicsreport.pdf}. The report highlights that biosimilars are a game for deep pockets. The medium or small generic firms are not likely to have sufficient capital and equipment to participate in the competition. Therefore, biosimilar development is likely to be a war among brand-name companies.

\textsuperscript{228} See Linda A. Johnson, \textit{Merck, Samsung JV Team Up on Biosimilar Medicines}, \textit{BLOOMBERG BUSINESSWEEK} (Feb. 20, 2013), \url{http://www.businessweek.com/ap/2013-02-20/merck-samsung-jv-team-up-on-biosimilar-medicines} (noting that Merck, a brand-name drug company, collaborated with Samsung in a joint venture to develop biosimilars).

\textsuperscript{229} See Peter Loftus, \textit{Merck Teams Up with Parexel on Biosimilars}, \textit{WALL ST. J.}, Jan. 12, 2011, \url{http://online.wsj.com/article/SB10001424052748704803604576078160079036994.html} (noting that Merck, Pfizer, and some other big brand-name drug makers view biosimilars as a big market opportunity and aim to participate as FOB companies); \textit{see also Pfizer Carrying out Biosimilar Trastuzumab Trial in US, GENERICS & BIOSIMILARS INITIATIVE} (Oct 19, 2012), \url{http://www.gabionline.net/Biosimilars/Research/Pfizer-carrying-out-biosimilar-trastuzumab-trial-in-US}. Pfizer is carrying out
D. STRIKING A BETTER BALANCE: A SIX-YEAR DATA EXCLUSIVITY AND A DYNAMIC SIX-TO-TWELVE-YEAR MARKET EXCLUSIVITY

A rigid, twelve-year FDA exclusivity, regardless of whether it is data or market exclusivity, is too long and tips the scale in favor of innovator companies. As articulated previously, a twelve-year exclusivity period is likely to outlive the underlying patents in the majority of the cases and eliminates the incentives to challenge these patents. This works against the public interest of promoting drug accessibility, especially in view of the high market entrance barrier and evergreening tactics in biologic therapies. However, reducing the FDA exclusivity straight to a rigid seven-year time frame, as President Obama suggested, might tip the scale too favorably toward the FOB companies’ side. In striking a better balance, this Note suggests a regulatory scheme of a six-year data exclusivity and a six-to-twelve-year dynamic market exclusivity. The dynamic market exclusivity would be adjudicated by a panel of experts from both the FTC and the FDA at the end of the six-year period.

Under this scheme, innovator companies have six years of absolute market monopoly covered by patent exclusivity, data exclusivity, and market exclusivities. During this period, an FOB referencing Trastuzumab, a biologic made by Roche to treat breast cancer; Trastuzumab is Roche’s third-best-selling drug. Id.

230. See supra Part II.B. In a nutshell, Part II.B. argues that (1) in view of the natural delicacy of biologics, it is difficult to produce biosimilars; to enter the biologics market requires large capital and advanced technologies compared to entering the market of small-molecule drugs; (2) a twelve-year exclusivity period is likely to outlive the underlying patents in the majority of the cases and eliminates the incentives to challenge the patents; and (3) a twelve-year period is likely to aggregate the negative impacts of evergreening tactics on drug-price competition, especially if the FDA adopted the tweak-to-renew policy.

231. See supra Part II.B.

232. See Palmedo, supra note 205. President Obama and proponents of generic drug companies supported a seven-year exclusivity. This Note’s Author believes a rigid seven-year period is too short and is not sufficient for innovator companies to recoup their investments. The reasons that justify innovator companies having FDA exclusivity longer than seven years are articulated in Part II.A of this Note: (1) it costs a lot more to develop a biologic therapy than a small-molecule drug; (2) biotechnology patents are particularly vulnerable to being challenged; and (3) innovation decreases steadily under the Hatch-Waxman incentive system.

233. See generally Bagley, supra note 48. During the first six years, an innovator company would have all three kinds of market exclusivities: patent exclusivity, data exclusivity, and market exclusivity. Patent exclusivity prevents FOB companies from using, selling, or importing the protected
innovator companies will face no competition, even if the underlying patents are invalidated. At the end of the six-year period, the FTC and the FDA will assemble an expert panel to adjudicate how many more years of market exclusivity will be granted. In the adjudication process, there should be trial-type procedures allowing the innovator companies to submit briefs, present experts, answer questions, and orally advocate their positions. The benefit of having this adjudication at the end of the six-year period is that it allows the FTC and the FDA to evaluate the sales profile of the biologic during that first five to six years. This sales information is extremely helpful in evaluating how many more years of market exclusivity should be granted to allow innovator companies to recoup their investments.

Some commentators might argue that this individualized adjudication is inefficient and will consume heavy administrative resources. This Note disagrees. According to the FDA, the number of approved BLAs was four in 2008, seven in 2009, six in 2010, and six in 2011. Since the annual number

---

biologic. Data exclusivity prevents FOB companies from submitting an ABLA. Market exclusivity prevents the FDA from approving an ABLA. The overlapping protection of all three exclusivity powers provides innovator companies with absolute market monopoly power.

234. See Tzeng, supra note 68, at 156 (explaining that FDA exclusivity is independent from patent exclusivity).

235. See generally EMERGING HEALTH CARE ISSUES, supra note 227. The FTC has the expertise in balancing customer protection and market monopoly (e.g., antitrust enforcement). The FDA has the expertise in assessing the technology and clinical effects of the biologic. Thus, an expert panel from both the FTC and the FDA will be ideal in adjudicating the market exclusivity.


237. See Grabowski, supra note 63, at 485 (demonstrating that mean sales of a biologic therapy grow almost linearly from the first year, at $128 million per year, to the ninth year, peaking at $713 million per year; the sales slightly decrease after the ninth year but remain above $600 million through the fourteenth year). Thus, having the first five to six years of sales data helps the expert panels from the FTC and the FDA to accurately predict how many more years an innovator company will need to recoup its investment.

238. Id.

of approved BLAs constantly remains single digit, adjudication for each BLA will not impose undue burden on the administrative system.

In promoting innovation, this suggested scheme recognizes the heavy up-front investment in developing a new biologic therapy and provides mechanisms to adjudicate individualized market exclusivity for innovator companies to recoup their investments. The innovator companies may present evidence showing how much money they have spent on bringing the biologic to the market and argue for how many more years they need to recoup the investments. In promoting accessibility, this suggested scheme avoids the potential extension of market monopoly due to FOB companies’ inability to complete the ABLA approval process before the expiration of innovators’ market exclusivity. This is because FOB companies can submit ABLAs at the end of the six-year period (i.e., the expiration of the data exclusivity, under this scheme) and use the expected three to four years of ABLA approval process to finish the required clinical trials and regulatory review. The

240. See Grabowski, supra note 63, at 489.

241. See supra Part II.B.2. If the twelve-year FDA exclusivity is explained as a data exclusivity, ABLA applicants can submit applications only after the expiration of the twelve-year data exclusivity and take another three to four years to finish the FDA approval process. This de facto extends innovators’ market monopoly period.

242. Trends in NDA and BLA Submissions and Approval Times, supra note 172. Since no ABLA has been approved by the FDA yet, no one knows how long it would take for an FOB to be approved by the FDA. But we can do some guess-work from the empirical data of innovator biologics and generic small-molecule drugs. The average approval time for innovator biologics (i.e., BLAs) should be the upper limit for an ABLA because the ABLA refers to a BLA’s clinical data. This means a much smaller scale of clinical trials and that it should take a shorter time to be approved than a BLA. On the other hand, the average approval time for generic small-molecule drugs (i.e., ANDA) should establish the lower limit for ABLA, because biologics normally take longer to be approved than small-molecule drugs. See Grabowski, supra note 63, at 482. An innovator biologic (i.e., BLA) takes on average 110 months to be approved, including both the time for clinical trials and regulatory review. See Kurt R. Karst, OGD’s ANDA Backlog and Median ANDA Approval Times Are Up—WAY UP! “The Solution Lies in Resources,” Says FDA Commissioner Hamburg, FDA L. BLOG (Feb. 25, 2010), http://www.fdalawblog.net/
ABLAs approval process will likely conclude before, or at least not long after, the expiration of the referenced biologic’s market exclusivity.243

This suggested scheme strikes a good balance for the incentives to bring patent invalidity challenges. The overall number of patent challenges will decrease compared to the current situation in small-molecule drugs. However, it does not eliminate the incentive to initiate patent invalidation challenges, contrary to the current rigid twelve-year FDA exclusivity. Invalidation challenges will be commenced by FOB companies in the case that the remaining patent term of the referenced biologic is longer than the adjudicated market exclusivity.244 The time difference between the remaining patent term and the adjudicated market exclusivity provides the additional profit margin that FOB companies gain by invalidating the patents.245 If the market exclusivity is equal to or longer than the remaining patent terms, there is no incentive for FOB companies to invalidate innovators’ patents because there is no extra profit margin.246

---

243. See Karst, supra note 49 (referencing a problem which this suggested scheme solves). A rigid twelve-year data exclusivity will cause unknown delay, perhaps stretching far after the expiration of the twelve-year data exclusivity period. This is because under the suggested scheme, FOB companies can submit ABLAs at the time the six-year data exclusivity expires and go through the clinical trial and regulatory review processes while the reference product market exclusivity is still ongoing. The ABLA approval process of, on average, three to four years is likely to be finished before, or at least not long after, the reference product market exclusivity expires.

244. See generally Drug Price Competition and Patent Term Restoration (Hatch-Waxman) Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585 (codified as amended in scattered sections of 15, 21, 28, and 35 U.S.C.). If the patents covering the reference biologic are invalidated, FOB companies can sell the competing product at the expiration of the reference biologic’s market exclusivity. See generally Ware & Littlefield, supra, note 64. If the reference biologic’s market exclusivity is equal to or longer than the underlying patents, FOB companies gain nothing by invalidating the patents because the biosimilar products will not be approved by the FDA until the market exclusivity expires anyway.

245. See Hemphill & Sampat, supra note 66, at 328 (discussing the process and incentives for generic drug-makers to challenge patents).

246. Id.
Finally, innovator companies will have a harder time engaging in evergreening tactics under this scheme.\footnote{247} During the trial-type adjudication, the experts from the FTC and the FDA and advocates from innovator companies will review factual information and engage in rigorous deliberation. This deliberation process makes it difficult for innovator companies to justify evergreening.\footnote{248}

CONCLUSION

Biologics promise cutting-edge therapies treating the toughest diseases faced in our time.\footnote{249} In October 2010, the BPCIA was enacted, establishing an abbreviated approval pathway for follow-on biologics, known as the biosimilar pathway.\footnote{250} Analogous to the Hatch-Waxman Act, the central mission of the BPCIA is to balance two competing interests: innovation and accessibility.\footnote{251} One of the most important provisions in the BPCIA is 42 U.S.C. § 262(k)(7)(A), which provides twelve-year FDA exclusivity.\footnote{252} At the time of this writing, it remains unclear whether this twelve-year FDA exclusivity is data or market exclusivity.\footnote{253} This Note concludes that this rigid twelve-year FDA exclusivity tips the balance toward innovation and compromises accessibility.\footnote{254} To strike a better balance, this Note proposes a six-year data exclusivity period and a six-to-twelve-year dynamic market exclusivity.

\footnote{247. \textit{See generally id.} (presenting responses to evergreening). In the adjudication process, the innovator companies will submit briefs, present experts, and orally advocate their positions for a longer period of market exclusivity. But if the biologic product at issue is a modified version of a previous product with minor or insignificant safety and efficacy improvements, the company will have a harder time convincing the expert panel to grant extra market exclusivity.}

\footnote{248. \textit{Id.}}

\footnote{249. \textit{See Patton, supra note 32.}}


\footnote{252. \textit{See Krauskopf, supra note 46.}}

\footnote{253. \textit{See Karst, supra note 49} (noting that the Commissioner of the FDA interpreted the twelve-year FDA exclusivity as a market exclusivity). On the other hand, some Senators and Representatives interpreted the twelve-year FDA exclusivity as data exclusivity. \textit{Id.}}

\footnote{254. \textit{See supra Part II.B.3 of this Note for detailed articulations.}}
scheme.\textsuperscript{255} In this scheme, experts from the FTC and the FDA will individually adjudicate a six-to-twelve-year market exclusivity period for each innovator biologic to ensure that innovator companies have a sufficient exclusive period to recoup their investment.\textsuperscript{256} This scheme allows ABLAs to be submitted at the expiration of the six-year data exclusivity period and allows FOBs to enter the market at or near the expiration of the market exclusivity period.\textsuperscript{257} The scheme reduces, yet does not eliminate, the incentives to challenge innovators’ patents.\textsuperscript{258} Finally, the scheme has the potential to halt evergreening.\textsuperscript{259} Thus, this regulatory scheme with \textit{six-year data exclusivity} and \textit{six-to-twelve-year dynamic market exclusivity} strikes a better balance between innovation and accessibility.

\textsuperscript{255} See supra Part II.D of this Note for detailed articulations.
\textsuperscript{256} See supra Part II.D.
\textsuperscript{257} See Karst, supra note 49.
\textsuperscript{259} See generally Hemphill & Sampat, supra note 66.